The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chih-Jen, Tsai, Ming-Ju, Hung, Jen-Yu, Lee, Mei-Hsuan, Tsai, Ying-Ming, Tsai, Yu-Chen, Hsu, Jui-Feng, Liu, Ta-Chih, Huang, Ming-Shyan, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729426/
https://www.ncbi.nlm.nih.gov/pubmed/29237484
http://dx.doi.org/10.1186/s40360-017-0190-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729426/
https://www.ncbi.nlm.nih.gov/pubmed/29237484
http://dx.doi.org/10.1186/s40360-017-0190-1

Ejemplares similares